Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,170 Shares

Key Points

• Insider David Malcom Rodman sold 2,170 shares on April 9 at an average price of $27.38 for $59,414.60, trimming his holdings to 76,140 shares (a 2.77% reduction); the sale was made under a pre‑arranged Rule 10b5-1 plan and follows multiple sizable sales earlier this year.
• MLYS traded around $27.16 (up ~2%) with a market cap near $2.24 billion and a one‑year range of $12.59–$47.65, while analysts maintain a consensus "Moderate Buy" rating and an average price target of $49.14.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 2,170 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $27.38, for a total transaction of $59,414.60. Following the sale, the insider owned 76,140 shares of the company's stock, valued at $2,084,713.20. This represents a 2.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total transaction of $173,744.76.
• On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total transaction of $369,163.08.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total transaction of $58,269.64.
• On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total transaction of $11,505.03.
• On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total transaction of $184,057.51.
• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.44, for a total transaction of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total transaction of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.10, for a total transaction of $13,353.60.
• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total transaction of $252,469.75.

Mineralys Therapeutics Trading Up 2.0%

MLYS stock traded up $0.54 on Monday, hitting $27.16. The company's stock had a trading volume of 584,382 shares, compared to its average volume of 1,347,260. The firm has a 50 day moving average of $27.35 and a two-hundred day moving average of $34.48. Mineralys Therapeutics, Inc. has a 1 year low of $12.59 and a 1 year high of $47.65. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -11.46 and a beta of 0.69.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. As a group, equities analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Mineralys Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Simplify Asset Management Inc. acquired a new position in shares of Mineralys Therapeutics during the 3rd quarter worth $8,294,000. Hudson Bay Capital Management LP acquired a new position in shares of Mineralys Therapeutics during the 3rd quarter worth $2,873,000. Vanguard Group Inc. grew its stake in shares of Mineralys Therapeutics by 29.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company's stock worth $114,480,000 after purchasing an additional 692,550 shares during the period. Citigroup Inc. grew its stake in shares of Mineralys Therapeutics by 501.7% during the 3rd quarter. Citigroup Inc. now owns 163,168 shares of the company's stock worth $6,187,000 after purchasing an additional 136,050 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Mineralys Therapeutics by 130.7% during the 4th quarter. SG Americas Securities LLC now owns 230,795 shares of the company's stock worth $8,376,000 after purchasing an additional 130,758 shares during the period. 84.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on MLYS shares. Stifel Nicolaus upped their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, December 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, March 15th. Bank of America boosted their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a "buy" rating in a research note on Friday, March 13th. Finally, HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the company a "buy" rating in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Mineralys Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $49.14.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.